Floatz logo

ATORVASTATIN

Cardiovascular Disorder

Duke UniversitySmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
89/ 100

Competitive context

54 Active assets in the Cardiovascular Disorder cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB
RAMIFENTANYL
Helse Fonna
Phase 4BBB

View all 50 →

Same molecule, other indications

ATORVASTATIN is also rated in:

inherited lipid metabolism disorderActive
A
Indicative · Phase 4
83 / 100
View asset →
hyperlipidemiaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BBB
Indicative · Phase 4
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →